Identification of Proteins Participating in the Cisplatin Resistance Following Treatment with Cisplatin in A2780 and A2780CP Ovarian Cell Lines Proteomics analysis of cisplatin resistance in A2780 cell line
Trends in Peptide and Protein Sciences,
Vol. 5 (2020),
4 March 2020
Ovarian cancer is the most fatal gynecological cancer and the 8th most prevalent type of cancer in Iran. Chemotherapy regimen for the treatment of this type of cancer is mostly based on platinum agents and paclitaxel. The major problem during treatment with cisplatin is the appearance of acquired resistance in cancer cells in the first 6 months of therapy. Owing to inefficacy of second line regimens, it seems necessary to find out the molecular mechanisms of cisplatin resistance and find an efficient strategy against the resistant cancer cells. In this study, two ovarian cancer cell lines, A2780-sensitive and A2780CP (resistant to cisplatin) were evaluated. To acquire the protein expression profile, a culture of each line containing 1.5×107 cells was divided into the two groups of control and treatment cells. The treatment group cells were treated with cisplatin at pre-determined IC50 concentration for 6 hours. Then, the total proteins of 7×106 cells were extracted. The proteome of each group (20 μg) was used for subsequent separation of proteins by two-dimensional gel electrophoresis using 7 cm IPG strips. The results of protein pattern changes were analyzed by one-way ANOVA. At least 230 proteins were detected in each gel, from which, about 45 proteins were differentially expressed in each model of comparison. However, by considering the results of all models of analysis on the protein expression profile of two cell lines, three proteins were determined as the key players of resistance against cisplatin.
- The major problem during treatment with cisplatin is the appearance of acquired resistance in cancer cells.
- The cisplatin- resistant and sensitive ovarian cell lines of A2780 were evaluated in this study.
- Proteomics analysis was run using 2D gel electrophoresis after cisplatin treatment.
- Three proteins were determined as the key players of resistance against cisplatin in A2780 cell line.
- Drug resistance
- Ovarian cancer
- Two-dimensional gel electrophoresis
How to Cite
Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Berek, J. S., Chen, L. M., Cristea, M., DeRosa, M., ElNaggar, A. C., Gershenson, D. M., Gray, H. J., Hakam, A., Jain, A., Johnston, C., Leath, C. A., Liu, J., Mahdi, H., Matei, D., McHale, M., McLean, K., O'Malley, D. M., Penson, R. T., Percac-Lima, S., Ratner, E., Remmenga, S. W., Sabbatini, P., Werner, T. L., Zsiros, E., Burns, J. L. and A. M. Engh, (2019). "NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019." Journal of the National Comprehensive Cancer Network, 17(8): 896-909.
Castagna, A., Antonioli, P., Astner, H., Hamdan, M., Righetti, S. C., Perego, P., Zunino, F. and P. G. Righetti, (2004). "A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431." Proteomics, 4(10): 3246-3267.
Chevallet, M., Luche, S. and T. Rabilloud, (2006). "Silver staining of proteins in polyacrylamide gels." Nature Protocols, 1(4): 1852-1858.
Dasari, S. and P. B. Tchounwou, (2014). "Cisplatin in cancer therapy: molecular mechanisms of action." European Journal of Pharmacology, 740: 364-378.
Davis, A., Tinker, A. V. and M. Friedlander, (2014). ""Platinum resistant" ovarian cancer: what is it, who to treat and how to measure benefit?" Gynecologic Oncology, 133(3): 624-631.
Huang, Q., Dunn, R. T., Jayadev, S., DiSorbo, O., Pack, F. D., Farr, S. B., Stoll, R. E. and K. T. Blanchard, (2001). "Assessment of cisplatin-induced nephrotoxicity by microarray technology." Toxicological Sciences, 63(2): 196-207.
Huq, F., Yu, J. Q., Beale, P., Chan, C., Arzuman, L., Nessa, M. U. and M. E. Mazumder, (2014). "Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer." Anticancer Research, 34(1): 541-545.
Jamali, B., Nakhjavani, M., Hosseinzadeh, L., Amidi, S., Nikounezhad, N. and S. F Hosseini Shirazi, (2015). "Intracellular GSH alterations and its relationship to level of resistance following exposure to cisplatin in cancer cells." Iranian Journal of Pharmaceutical Research, 14(2): 513-519.
Kim, J. W., Sahm, H., You, J. and M. Wang, (2010). "Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells." Anticancer Research, 30(7): 2577-2581.
Ledermann, J. A., Raja, F. A., Fotopoulou, C., Gonzalez-Martin, A., Colombo, N. and C. Sessa, (2013). "Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of Oncology, 24(Suppl 6): vi24-32.
Lincet, H., Guevel, B., Pineau, C., Allouche, S., Lemoisson, E., Poulain, L. and P. Gauduchon, (2012). "Comparative 2D-DIGE proteomic analysis of ovarian carcinoma cells: toward a reorientation of biosynthesis pathways associated with acquired platinum resistance." Journal of Proteomics, 75(4): 1157-1169.
Muggia, F. (2009). "Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer." Gynecologic Oncology, 112(1): 275-281.
Schilder, R. J., Hall, L., Monks, A., Handel, L. M., Fornace, A. J., Ozols, R. F., Fojo, A. T. and T. C. Hamilton, (1990). "Metallothionein gene expression and resistance to cisplatin in human ovarian cancer." International Journal of Cancer, 45(3): 416-422.
Sorenson, C. M., Barry, M. A. and A. Eastman, (1990). "Analysis of events associated with cell cycle arrest at G2 phase and cell death induced by cisplatin." Journal of the National Cancer Institute, 82(9): 749-755.
Stewart, D. J. (2007). "Mechanisms of resistance to cisplatin and carboplatin." Critical Reviews in Oncology/Hematology, 63(1): 12-31.
Webb, P. M. and S. J. Jordan, (2017). "Epidemiology of epithelial ovarian cancer." Best Practice & Research: Clinical Obstetrics & Gynaecology, 41: 3-14.
Will, J., Wolters, D. A. and W. S. Sheldrick, (2008). "Characterisation of cisplatin binding sites in human serum proteins using hyphenated multidimensional liquid chromatography and ESI tandem mass spectrometry." ChemMedChem, 3(11): 1696-1707.
Wu, Y., Zhou, J., Zhang, X., Zheng, X., Jiang, X., Shi, L., Yin, W. and J. Wang, (2009). "Optimized sample preparation for two-dimensional gel electrophoresis of soluble proteins from chicken bursa of Fabricius." Proteome Science, 7: 38.
Zhou, J., Wei, Y. H., Liao, M. Y., Xiong, Y., Li, J. L. and H. B. Cai, (2012). "Identification of cisplatin-resistance associated genes through proteomic analysis of human ovarian cancer cells and a cisplatin-resistant subline." Asian Pacific Journal of Cancer Prevention, 13(12): 6435-6439.
- Abstract Viewed: 79 times
- PDF Downloaded: 50 times